Category Archives: DNA

DNA Test Shows Ohio Kidnap Suspect Fathered Girl
http://www.youtube.com/channel/UC8y4sRt4LVjqtdxbaMR0Nmw DNA Test Shows Ohio Kidnap Suspect Fathered Girl ABC News - lrm;54 minutes ago lrm; As relatives of the Clev...

By: mary Angelas

See original here:
DNA Test Shows Ohio Kidnap Suspect Fathered Girl - Video

Digimon World 2 [Part 9][Double dna digivolve]
#1051; #1077; #1090; #1089; #1087; #1083; #1077; #1081; #1044; #1080; #1075; #1080; #1084; #1086; #1085; #1042; #1086; #1088; #1083; #1076; 2. #1048; #1075; #1088; #1086; #1074; #1086; #1081; #1082; #1072; #1085; #1072; #1083;: http://www.youtube.com/user/hodgepodgedude #1046; #1080; #1074; #1086; #1081; #1082; #1072; #1085; #1072; #1083;: http://www.youtube.com/user/hodgepodgedudelive #1047; #1072; #1087; #1072; #1089; #1085; #1086; #1081; #1082; #1072; #1085; #1072;...

By: angel000ist

See the original post:
Digimon World 2 [Part 9][Double dna digivolve] - Video

Barrie Trower (Clip 1 of 14) - Irreparable DNA Damage from Non-Ionising Radiation
DNA damage caused by microwave radiation is irreparable. It is passed on from mother to daughter, generation after generation... for ever.

By: SSITAorgUK

The rest is here:
Barrie Trower (Clip 1 of 14) - Irreparable DNA Damage from Non-Ionising Radiation - Video

DNA bound to HAPE1 strand 1
Cancer Prevention: How Abasic site bound to the active pocket of Human AP Endonuclease is removed and replaced in DNA repair.

By: MedicalBiosciences

View post:
DNA bound to HAPE1 strand 1 - Video

Jetts Coolum DNA
This is our entry into a completion that Head Office is running. The clip had to have the Jetts DNA and a coconut in it!! Check it out and have a giggle at o...

By: Jetts Coolum

Original post:
Jetts Coolum DNA - Video

DNA Face Sculptures And More... -- BiDiPi #33
Your BiDiPi 33: http://bit.ly/YFAy2Z BiDiPi Radio: http://bit.ly/17ZEmis **** CLICK "SHOW MORE" FOR LINKS TO EVERYTHING **** Watch Me On Nerdy Nummies: http:...

By: Vsauce2

Read this article:
DNA Face Sculptures And More... -- BiDiPi #33 - Video

BLUE BELL, Pa., May 14, 2013 /PRNewswire/ --Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study of Inovio's SynCon DNA vaccine against Ebola and Marburg filoviruses, labeled "Category A" bioterrorism agents by the U.S. government, the vaccine induced strong and broad immune responses and demonstrated 100% protection against death following a challenge with multiple variants of the pathogen in two animal models.

There is no approved vaccine or therapy available against these highly virulent pathogens that have killed up to 90% of the people they infected. Because these viruses could potentially be easily transmitted, result in high mortality rates and cause a major public health impact, various agencies are seeking solutions for public health preparedness. A DNA vaccine could offer faster design and manufacturing timelines than traditional vaccine approaches, but particularly important, Inovio's SynCon products offer the potentially preemptive advantage of enabling a design to provide broad protection encompassing multiple families of these so-called filoviruses.

Preclinical data was published in the peer-reviewed journal Molecular Therapy in a paper, "Induction of Broad Cytotoxic T Cells by Protective DNA Vaccination Against Marburg and Ebola," authored by Inovio researchers and collaborators.

Using Inovio's proprietary SynCon design approach, Inovio researchers developed a polyvalent DNA vaccine consisting of three consensus plasmids to broadly target variant virus strains within three distinct families of Ebola and Marburg viruses. In the first part of this study, following two vaccinations using Inovio's proprietary CELLECTRA electroporation device, 100% of vaccinated guinea pigs were protected from death following a virus challenge. The researchers observed significant increases in neutralizing antibody titers and strong and broad levels of vaccine-induced T-cells, including "killer" T-cells, and subsequently conducted a test in mice using only one vaccination this single dose also fully protected the animals from death following a virus challenge. In addition, unlike the non-vaccinated animals, vaccinated animals were protected from weight loss.

Dr. Joseph Kim, Inovio's President and CEO said, "This study again demonstrates the preventive potency and broad immune response that we consistently see in studies of our DNA portfolio of vaccines. These immune response characteristics are the type considered necessary to achieve protection in humans. These outstanding results support Inovio's active biodefense program, which has garnered multiple grants from the Department of Defense, Defense Threat Reduction Agency (DTRA), National Institute of Allergy and Infectious Diseases (NIAID), and other government agencies focused on public health which value our DNA vaccine approach to treating and preventing disease."

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon vaccines are designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include phase II studies for cervical dysplasia, leukemia and hepatitis C virus and phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at http://www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended March 31, 2013, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:

Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com

Read more:
Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical ...

The Minoans, the builders of Europe's first advanced civilization, really were European, new research suggests.

The conclusion, published today (May 14) in the journal Nature Communications, was drawn by comparing DNA from 4,000-year-old Minoan skeletons with genetic material from people living throughout Europe and Africa in the past and today.

"We now know that the founders of the first advanced European civilization were European," said study co-author George Stamatoyannopoulos, a human geneticist at the University of Washington. "They were very similar to Neolithic Europeans and very similar to present day-Cretans," residents of the Mediterranean island of Crete.

While that may sound intuitive, the findings challenge a long-held theory that the ancient Minoans came from Egypt.

First European Civilization

The Minoan culture emerged on Crete, which is now part of Greece, and flourished from about 2,700 B.C. to 1,420 B.C. Some believe that a massive eruption from the Volcano Thera on the island of Santorini doomed the Bronze Age civilization, while others argue that invading Mycenaeans toppled the once-great power.

Nowadays, the Minoans may be most famous for the myth of the minotaur, a half-man, half-bull that was fabled to lived within a labyrinth in Crete. [10 Beasts & Dragons: How Reality Made Myth]

When British archaeologist Sir Arthur Evans discovered the Minoan palace of Knossos more than 100 years ago, he was dumbstruck by its beauty. He also noticed an eerie similarity between Minoan and Egyptian art, and didn't believe that the culture was homegrown.

"That's why Evans postulated the civilization was imported from Egypt or Libya," Stamatoyannopoulos told LiveScience.

Genetic clues

Visit link:
Mysterious Minoans Were European, DNA Finds

Public domain

The Greek hero Theseus slays the minotaur in this 6th-century depiction on pottery. Nowadays, the Minoans may be most famous for the myth of the minotaur, a half-man, half-bull that was fabled to have lived within a labyrinth in Crete.

By Tia Ghose LiveScience

The Minoans, the builders of Europe's first advanced civilization, really were European, new research suggests.

The conclusion, published Tuesdayin the journal Nature Communications, was drawn by comparing DNA from 4,000-year-old Minoan skeletons with genetic material from people living throughout Europe and Africa in the past and today.

"We now know that the founders of the first advanced European civilization were European," said study co-author George Stamatoyannopoulos, a human geneticist at the University of Washington. "They were very similar to Neolithic Europeans and very similar to present day-Cretans," residents of the Mediterranean island of Crete.

While that may sound intuitive, the findings challenge a long-held theory that the ancient Minoans came from Egypt.

First European civilizationThe Minoan culture emerged on Crete, which is now part of Greece, and flourished from about 2,700 B.C. to 1,420 B.C. Some believe that a massive eruption from the Volcano Theraon the island of Santorini doomed the Bronze Age civilization, while others argue that invading Mycenaeans toppled the once-great power.

Nowadays, the Minoans may be most famous for the myth of the minotaur, a half-man, half-bull that was fabled to have lived within a labyrinth in Crete. [10 Beasts & Dragons: How Reality Made Myth]

When British archaeologist Sir Arthur Evans discovered the Minoan palace of Knossos more than 100 years ago, he was dumbstruck by its beauty. He also noticed an eerie similarity between Minoan and Egyptian art, and didn't believe that the culture was homegrown.

See the rest here:
Mysterious Minoans really were European, DNA finds

By Barbara Liston

SANFORD (Reuters) - Lawyers seeking to overturn the murder conviction of a Honduran man who has been on Florida's death row since 2006 presented new DNA and blood stain evidence in a Florida court on Tuesday.

Clemente Aguirre-Jarquin, 33, was convicted in the 2004 murders of his neighbors at a Seminole County trailer park. Cheryl Williams, 47, was stabbed 129 times, and her mother, Carol Bareis, 69, was stabbed twice.

Blood stain expert Barie Goetz testified Tuesday that the killer would have been splattered with blood spurting from 131 stab wounds from a 10-inch knife at close range. Goetz said the blood found on the thigh area of Aguirre's shorts were contact stains and matched Aguirre's claim that he found the bodies and rolled them over to check for a pulse.

"The wearer of those shorts did not inflict the injuries to Cheryl Williams," said Goetz, a Pennsylvania-based forensic consultant. Goetz also testified that Aguirre's bloody shoe prints at the scene indicated careful walking around the bodies.

The Innocence Project, which is dedicated to using DNA testing to exonerate those who are wrongly convicted, and Aguirre's appellate legal team also obtained DNA analysis of some of the 150 blood stains photographed and swabbed at the crime scene but never tested.

NEW DNA EVIDENCE

The new DNA analysis concluded that eight blood stains at the crime scene matched Samantha Williams, the daughter and granddaughter of the victims, and none matched Aguirre, according to a report by the Innocence Project.

Samantha Williams had a history of mental illness, and during two mental breakdowns after Aguirre's conviction confessed to the killings, according to the report. Witnesses also said Samantha and her mother had a heated argument before the killings, and that Samantha sent her boyfriend to her mother's trailer the next morning, saying she had a "bad feeling" something had happened to her.

Nina Morrison, a lawyer for the Innocence Project, told Reuters that Samantha Williams has been subpoenaed to testify Wednesday.

The rest is here:
DNA evidence may clear Honduran man sentenced to death in Florida